Direct-to-consumer Marketing to People with Hemophilia

Adriane Fugh-Berman and colleagues describe how strategies similar to those used to market drugs to physicians are directed towards people with hemophilia.

Vyšlo v časopise: Direct-to-consumer Marketing to People with Hemophilia. PLoS Med 13(6): e32767. doi:10.1371/journal.pmed.1001996
Kategorie: Policy Forum


Adriane Fugh-Berman and colleagues describe how strategies similar to those used to market drugs to physicians are directed towards people with hemophilia.


1. Sah S, Fugh-Berman A. Physicians under the influence: Social psychology and industry marketing strategies. J Law Med Ethics. 2013;41(3):665–72. doi: 10.1111/jlme.12076 24088157

2. Fugh-Berman A, Melnick D. Off-label promotion, on-target sales. PLoS Med. 2009;5(10):e210.

3. Fugh-Berman A, Ahari S. Following the script: How drug reps make friends and influence doctors. PLoS Med. 2007;4(4):e150. 17455991

4. Accreditation Council for Continuing Medical Education. Accreditation Council for Continuing Medical Education (ACCME®) 2014 Annual Report. 2015 July 7, 2015.

5. Mintzes B. Advertising of prescription-only medicines to the public: Does evidence of benefit counterbalance harm? Ann Rev Public Health. 2012 Apr;33:259–77. doi: 10.1146/annurev-publhealth-031811-124540

6. Frosch DL, Grande D, Tarn DM, Kravitz RL. A decade of controversy: Balancing policy with evidence in the regulation of prescription drug advertising. Am J Public Health. 2010 Jan;100(1):24–32. doi: 10.2105/AJPH.2008.153767 19910354

7. Soucie M J, Evatt B, Jackson D. Occurrence of hemophilia in the United States. Am J Hematol. 1998;59:288–94. 9840909

8. Evatt BL. Demographics of hemophilia in developing countries. Semin Thromb Hemost. 2005;31(5):489–94. 16276455

9. United States Government Accountability Office. Medicare: Payment for Blood Clotting Factor Exceeds Providers' Acquisition Cost. 2003;Rep.No. GAO-03-184. U.S. Government Printing Office, Washington DC,

10. Butler R, McClure W, Wulff K. Practice patterns in haemophilia A therapy—A survey of treatment centers in the United States. Haemophilia. 2003;9:549–54. 14511293

11. Geraghty A, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy—Global progress towards optimal care. Haemophilia. 2006;12:75–81. 16409179

12. Richards M, Altisent C, Batorova A, Chambost H, dolan G, de Moerloose P, et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia. 2007;13:473–9. 17880432

13. Stevens C. Developing standards of protocol in hemophilia. ProphyDose. 2008 Nov;5.

14. Morningstar Healthcare Observer. The Hemophilia Market: Steep but Surmountable Barriers for New Entrants. 2013 Jan. p. 1–38. Accessed: March 30, 2015.

15. IMS Health. Top 20 Global Products, 2011, Total Audited Markets. IMS Health MIDAS. 2011 Dec.

16. Milliman Inc. client report. An Actuarial Study of Hemophilia: Implications for Commercial and Medicaid Managed Care Plans. Prepared for Baxter Health Corporation. 2013 Oct. Accessed: March 1, 2015.

17. Zhou ZY, Koerper MA, Johnson KA, Riske B, Baker JR, Ullman M, et al. Burden of illness: direct and indirect costs among persons with hemophilia A in the United States. J Med Econ. 2015 Feb;7:1–28.

18. Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood. 2012;119(18):4108–14. doi: 10.1182/blood-2012-01-394411 22411872

19. Rogoff EG, Guirguis HS, Lipton RA, Seremetis SV, DiMichele DM, Agnew GM, et al. The upward spiral of drug costs: a time series analysis of drugs used in the treatment of hemophilia. Thromb Haemost. 2002;88:545–53. 12362223

20. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–44. 17687129

21. Armstrong EP, Malone DC, Krishnan S, MJ W. Costs and utilization of hemophilia A and B patients with and without inhibitors. J Med Econ. 2014 Aug;20:1–5.

22. Carlsson KS, Hojgard S, Lindgren A, Lethagen S, Schulman S, Glomstein A, et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia, 2004;10(5): 515–526. 15357779

23. Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost. 2014 Jul;40(5):571–6. doi: 10.1055/s-0034-1381232 24911674

24. Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia. 2012 Mar;18(2):276–83. doi: 10.1111/j.1365-2516.2011.02713.x 22188641

25. Johnson KA, Zhou ZY. Costs of care in hemophilia and possible implications of health care reform. Hematology Am Soc Hematol Educ Program. 2011:413–8. doi: 10.1182/asheducation-2011.1.413 22160067

26. Kelley L. Pharmaceutical direct–to-consumer marketing: When is it acceptable?: Patient Empowerment Newsletter; 2008 May. p. 1.

27. Baxter Healthcare Corporation [Internet]. Your online hemophilia resource. 2008. Accessed: February 17, 2012. Archived at: Accessed: February 5, 2016.

28. Rep Goes to Summer Camp. Pharmaceutical Representative; 1998 Oct.

29. Pollock A. Hemophilia Patient or Drug Seller? Dual Role Creates Ethical Quandary. New York Times. January 13, 2016. Accessed: February 5, 2016.

30. Biogen Idec [Internet]. Supporting the hemophilia community. 2015. Accessed: March 1, 2015.

31. Novo Nordisk Inc. [brochure]. Changing possibilities in hemophilia. Oct 2008. Princeton, New Jersey.

32. Novo Nordisk Health Care AG [Internet]. Changing possibilities in hemophilia. Accessed: December 30, 2014. Archived at: Accessed: February 3, 2016.

33. Hemophilia Village [Internet]. Scholarship Assistance. Accessed: February 2, 2016.

34. Hemophilia Village [Internet]. Resourcs and Support. Accessed: February 2, 2016.

35. Pfizer [Internet]. Xyntha Solofuse—Pfizer RxPathways. Accessed: February 4, 2016.

36. Baxalta [Internet]. The CARE Program. Accessed: February 5, 2016.

37. Baxalta [Internet]. What Can Baxalta's NAVA Program Do For You? Accessed: February 4, 2016.

38. Baxalta [Internet]. The NAVA Mentor Program. Accessed: February 4, 2016.

39. Bayer HealthCare Pharmaceuticals Inc. [Internet]. Living with Hemophilia. 2014. Accessed: March 30, 2015.

40. PR Newsire [Internet]. Bayer launches first interactive virtual walk in support of hemophilia [press release]. 2011 Apr 14. Accessed: March 30, 2015.

41. Pfizer [Internet]. Xyntha Solofuse. Accessed: March 30, 2015. Archived at: Accessed: February 4, 2016.

42. The American Thrombosis and Hemostasis Network [Internet]. Baxter Donates ADOY To ATHN. Accessed: February 3, 2016.

43. The American Thrombosis and Hemostasis Network [Internet]. 2010 Annual Report. Accessed: March 30, 2015.

44. Hemophilia Association of New Jersey. Services >> PACT. Accessed: January 23, 2016.

45. New England Hemophilia Association. Corporate Partners. Accessed: October 29, 2015.

46. Anonymous. Five years at the summit. Hemaware May 24, 2010.

47. Press Release. Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families. August 27, 2009.

48. National Hemophilia Foundation website [Internet]. Inhibitor Education Summits. Accessed: January 25, 2016.

49. National Hemophilia Foundation website [Internet]. Regional Inhibitor Conferences. Accessed: January 26, 2016.

50. National Hemophilia Foundation website [Internet]. Inhibitor Webinars. Accessed: January 26, 2016.

51. Pfizer website [Internet]. US Medical, Scientific, Patient and Civic Organization Funding Report: Fourth Quarter 2013. at Accessed: January 23, 2016.

52. Pfizer website [Internet]. US Medical, Scientific, Patient and Civic Organization Funding Report: Fourth Quarter 2014. at Accessed: January 23, 2016.

53. Pfizer website [Internet]. US Medical, Scientific and Patient Organizations Grant Report: Third quarter 2015. h at Accessed: January 23, 2016.

54. National Hemophilia Form 990. 2013. Accessed: March 22, 2015.

55. Abel GA, Neufeld EJ, Sorel M, Weeks JC. Direct-to-consumer advertising for bleeding disorders: A content analysis and expert evaluation of advertising claims. J Thromb Haemost. 2008;6:1680–684. doi: 10.1111/j.1538-7836.2008.03083.x 18647231

56. Arie S, Mahoney C. Should patient groups be more transparent about their funding? BMJ. 2014;349:g5892. doi: 10.1136/bmj.g5892 25266116

57. Ball DE, Tisocki K, Herxheimer A. Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey. BMC Public Health. 2006;6:201. 16887025

58. Batt S. Who will support independent patients' groups? BMJ. 2014;349:g6306. doi: 10.1136/bmj.g6306 25336232

59. Mintzes B. Should patient groups accept money from drug companies? No. BMJ. 2007;334:935. doi: 10.1136/bmj.39185.394005.AD 17478846

60. O'Mahony B, Kent A, Aymé S. Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) Congress: Changing the policy landscape: Haemophilia patient involvement in healthcare decision-making. Eur J Haematol Suppl. 2014 Jun(74):1–8. doi: 10.1111/ejh.12316 24801295

61. Durand M. Pharma's advocacy dance.; 2006 Oct 1.'s Advocacy Dance. Accessed: March 30, 2015.

Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine

2016 Číslo 6
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.


Nemáte účet?  Registrujte sa